Gilead Sciences agreed to buy Tubulis for up to $5 billion, expanding the pharma’s antibody-drug conjugate (ADC) toolkit beyond its Trodelvy and strengthening clinical ADC depth. The deal includes a $3.15 billion upfront payment and up to $1.85 billion in milestone contingent payments, with Tubulis operating as a dedicated ADC research organization within Gilead after close, expected in 2Q26. Tubulis’ lead asset, TUB-040, is a NaPi2b-directed topoisomerase I inhibitor ADC in Phase Ib/II NAPISTAR1-01 for platinum-resistant ovarian cancer and non-small-cell lung cancer. Tubulis also brings TUB-030, a 5T4-targeted ADC. Gilead said the acquisition follows a closely aligned collaboration and is aimed at enabling more selective payload delivery and reducing off-target exposure. In parallel with this acquisition spree, market coverage highlights that Gilead has recently added other oncology capabilities via deals in early 2026—underscoring an aggressive strategy to broaden both platform technology and clinical pipeline execution.